PAMS
CYTK icon

Pictet Asset Management (Switzerland)’s Cytokinetics CYTK Stock Holding History

Pictet Asset Management (Switzerland)’s Portfolio CYTK Stock Details CYTK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		$73.5M Sell
2,252,206
-18,185
-0.8% -$673K 0.09% 240
2023
Q1 		$79.9M Buy
2,270,391
+5,079
+0.2% +$207K 0.1% 228
2022
Q4 		$104M Buy
2,265,312
+109,947
+5% +$4.73M 0.15% 184
2022
Q3 		$104M Sell
2,155,365
-52,523
-2% -$2.53M 0.15% 182
2022
Q2 		$86.7M Sell
2,207,888
-342,175
-13% -$13.8M 0.12% 211
2022
Q1 		$93.9M Sell
2,550,063
-54,734
-2% -$1.94M 0.11% 222
2021
Q4 		$119M Buy
2,604,797
+214,005
+9% +$8.26M 0.12% 208
2021
Q3 		$83M Buy
+2,390,792
New +$70.4M 0.09% 252

Other funds holding CYTK

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

Pictet Asset Management (Switzerland)'s CYTK Position: Q2 2023 in Review

Pictet Asset Management (Switzerland) reduced its Cytokinetics (CYTK) stake by 0.8% in Q2 2023, selling an estimated $673K and leaving 2,252,206 shares worth $73.5M. The position accounts for 0.09% of the portfolio, ranked #240.

Pictet Asset Management (Switzerland) first reported a position in CYTK in Q3 2021 and has held it in 8 quarters since. The position peaked at $119M in Q4 2021. 253 funds tracked by Wall St. Rank hold CYTK as of Q2 2023.

  • Pictet Asset Management (Switzerland) held 2,252,206 shares of Cytokinetics worth $73.5M as of Q2 2023.
  • Pictet Asset Management (Switzerland) sold 18,185 Cytokinetics shares in Q2 2023, an estimated $673K.
  • Cytokinetics made up 0.09% of Pictet Asset Management (Switzerland)'s portfolio in Q2 2023, its #240 holding.
  • Pictet Asset Management (Switzerland) first reported a position in Cytokinetics in Q3 2021 and has held it in 8 quarters since.
  • Pictet Asset Management (Switzerland)'s Cytokinetics position peaked at $119M in Q4 2021.
  • 253 funds tracked by Wall St. Rank held Cytokinetics as of Q2 2023.

Based on Pictet Asset Management (Switzerland)'s 13F filing for Q2 2023, filed 10 Aug 2023.